Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 147, Issue 8, 2008, Pages 1431-1435

  Kereszturi, Eva ^a   Tarnok, Zsanett ^b   Bognar, Emese ^b   Lakatos, Krisztina ^c   Farkas, Luca ^b   Gadoros, Julia ^b   Sasvari Szekely, Maria ^a   Nemoda, Zsofia ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Vadaskert Child and Adolescent Psychiatric Clinic   (Hungary)

^c INSTITUTE FOR PSYCHOLOGY   (Hungary)

Author keywords

Attention deficit hyperactivity disorder; DAT1; Dopaminergic polymorphism; DRD4; Pharmacogenetics

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC TRAIT; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; SYMPTOM; TANDEM REPEAT;

ALLELES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHI-SQUARE DISTRIBUTION; CHILD; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; HUMANS; MALE; METHYLPHENIDATE; MINISATELLITE REPEATS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, DOPAMINE D4; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 57349196728     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30704     Document Type: Article

References (35)

1. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Press.
2. Balazs J, Biro A, Dalnoki D, Lefkoics E, Tamas Z, Nagy P, Gadoros J. 2004. The Hungarian adaptation of the M.I.N.I. KID. Psychiatr Hung 19:358-364.
3. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 57:289-300.
4. Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Fagan J, Gadoros J, Harpin V, Hazell P, Johnson M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D. 2004. A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 13:249-257.
5. Cheon KA, Ryu YH, Kim JW, Cho DY. 2005. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: Relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 15:95-9101.
6. Cheon KA, Kim BN, Cho SC. 2007. Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children. Neuropsychopharmacology 32:1431.
7. Cheuk DK, Wong V. 2006. Meta-analysis of association between a catechol-O-methyltransferase gene polymorphism and attention deficit hyperactivity disorder. Behav Genet 36:651-659.
8. DuPaul GJ. 1998. ADHD rating scale-IV: Checklists, norms and clinical interpretations. New York: Guilford Press.
9. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR. 2001. Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917-6922.
10. Eisenberg J, Mei-Tal G, Steinberg A, Tartakovsky E, Zohar A, Gritsenko I, Nemanov L, Ebstein RP. 1999. Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD). Association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. Am J Med Genet B Neuropsychiatr Genet 88:497-502.
11. Faraone SV, Wilens T. 2003. Does stimulant treatment lead to substance use disorders? J Clin Psychiatry 64(Suppl 11):9-13.
12. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P. 2005. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1313-1323.
13. Guy W. 1976. Clinical global impression. ECDEU assessment manual for psychopharmacology, National Institute of Mental Health, Rockville, MD.
14. Hamarman S, Fossella J, Ulger C, Brimacombe M, Dermody J. 2004. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: A pharmacogenetic study. J Child Adolesc Psychopharmacol 14:564-574.
15. Joober R, Grizenko N, Sengupta S, Amor LB, Schmitz N, Schwartz G, Karama S, Lageix P, Fathalli F, Torkaman-Zehi A, Stepanian MT. 2007. Dopamine transporter 3′-UTR VNTR genotype and ADHD: A pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology 32:1370-1376.
16. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. 2005. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: Amulticenter, randomized prospective study. Adv Ther 22:498-512.
17. Kereszturi E, Kiraly O, Csapo Z, Tarnok Z, Gadoros J, Sasvari-Szekely M, Nemoda Z. 2007. Association between the 120-bp duplication of the dopamine D4 receptor gene and attention deficit hyperactivity disorder: Genetic and molecular analyses. Am J Med Genet Part B 144B:231-236.
18. Kirley A, Lowe N, Hawi Z, Mullins C, Daly G, Waldman I, McCarron M, O'Donnell D, Fitzgerald M, Gill M. 2003. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet Part B 121B:50-54.
19. Langley K, Turic D, Peirce TR, Mills S, Van Den Bree MB, Owen MJ, O'Donovan MC, Thapar A. 2005. No support for association between the dopamine transporter (DAT1) gene and ADHD. Am J Med Genet Part B 139B:7-10.
20. Li D, Sham PC, Owen MJ, He L. 2006. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet 15:2276-2284.
21. Lott DC, Kim SJ, Cook EH Jr, de Wit H. 2005. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 30:602-609.
22. Masellis M, Basile VS, Muglia P, Ozdemir V, Macciardi FM, Kennedy JL. 2002. Psychiatric pharmacogenetics: Personalizing psychostimulant therapy in attention-deficit/hyperactivity disorder. Behav Brain Res 130:85-90.
23. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR. 2003. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 100:6186-6191.
24. McGough JJ. 2005. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 57:1367-1373.
25. Mick E, Biederman J, Spencer T, Faraone SV, Sklar P. 2006. Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. Am J Med Genet Part B 141B:890-894.
26. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. 2007. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 164:942-948.
27. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH. 2002. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 12:497-499.
28. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C, Kim SJ, Cook EH. 2005. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 30:1374-1382.
29. Swanson JM, Volkow ND. 2002. Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. Behav Brain Res 130:73-78.
30. Tahir E, Curran S, Yazgan Y, Ozbay F, Cirakoglu B, Asherson PJ. 2000. No association between low- and high-activity catecholamine-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Am J Med Genet B Neuropsychiatr Genet 96:285-288.
31. Tarnok Z, Ronai Z, Gervai J, Kereszturi E, Gadoros J, Sasvari-Szekely M, Nemoda Z. 2007. Dopaminergic candidate genes in Tourette syndrome: Association between tic severity and 3′ UTR polymorphism of the dopamine transporter gene. Am J Med Genet Part B 144B:900-905.
32. Tunbridge EM, Harrison PJ, Weinberger DR. 2006. Catechol -O-methyltransferase, cognition, and psychosis: Val(158)Met and beyond. Biol Psychiatry 60:141-151.
33. van der Meulen EM, Bakker SC, Pauls DL, Oteman N, Kruitwagen CL, Pearson PL, Sinke RJ, Buitelaar JK. 2005. High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD. J Child Psychol Psychiatry 46:1074-1080.
34. Winsberg BG, Comings DE. 1999. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 38:1474-1477.
35. Zeni CP, Guimaraes AP, Polanczyk GV, Genro JP, Roman T, Hutz MH, Rohde LA. 2007. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am J Med Genet Part B 144B:391-394.